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Background: To evaluate the relationship between cyclin D1 overexpression and bladder cancer prognosis.
Methods: A systematic literature search up to July 27, 2013 was carried out in PubMed and Wanfang databases,
and the references of retrieved articles were screened. The hazard ratios (HRs) and their 95% CIs were used to
combine the data. Heterogeneity and publication bias were also evaluated.
Results: A total of 15 studies containing 2,591 cases were included. We found that increased cyclin D1 levels were
significantly correlated with progression-free survival with a pooled HR estimate of 0.54 (95% CI: 0.32–0.92). There
was a significant degree of heterogeneity (I2 = 93.8%, P <0.001). Moreover, subgroup analysis indicated that elevated
cyclin D1 levels were significantly associated with overall survival in muscle-invasive bladder patients (HR: 0.95,
95% CI: 0.91–0.99), without a significant heterogeneity in the data (I2 = 0.0%, P = 0.456).
Conclusions: Increased cyclin D1 expression level detected by immunohistochemistry is associated with good
progression-free survival for bladder cancer. Because of the limited number of studies, further well-designed
prospective studies are warranted to confirm the findings from our study.
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Urothelial bladder cancer ranks ninth in worldwide can-
cer incidence; it is the seventh most common malig-
nancy in men and seventeenth in women [1]. Despite
advances in treatment, the prognosis of bladder cancer,
especially muscle-invasive tumors, remains poor. An es-
timated 386,300 new cases and 150,200 deaths from
bladder cancer occurred in 2008 worldwide [2].
Recently, increasing attention is being paid to the prog-
nostic biomarkers in bladder cancer patients. Although
genes associated with epithelial-mesenchymal transition
(e.g., E-cadherin), apoptosis (e.g., p53), and angiogenesis
(e.g., VEGF) have been investigated by several studies, the
identification of a well-established marker possessing the
predictive value for survival of bladder cancer patients re-
mains a topic that needs to be explored [3-5].
Cyclin D1 (CCND1) is located on chromosome 11q13.
As a key regulator of the G1 progression step within the
cell cycle, it is a major positive regulator of the G1* Correspondence: wusongdi@gmail.com
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unless otherwise stated.restriction point [6]. Cyclin D1 expression is altered in
various cancers, suggesting that its deregulation contrib-
utes to tumorigenesis. For bladder cancer, cyclin D1 also
has been reported to play an important role in origin,
development, and dissemination of the disease [7]. How-
ever, in previous studies, the association between tissue
expression of cyclin D1 and carcinogenesis and/or clin-
ical outcome remains inconclusive. Cyclin D1 protein
expression has been reported to be correlated with both
poor and good prognosis, partially since a single study
might be too underpowered to detect a possible small ef-
fect of cyclin D1 expression on bladder cancer progno-
sis, especially when the sample size is relatively small. In
this study, we conducted a systematic review and meta-
analysis to estimate the effect of cyclin D1 altered ex-
pression on the survival of bladder cancer patients.Methods
Publication search
We carried out a search in PubMed and Wanfang data-
bases, covering all the papers published from their in-
ception to July 27, 2013, using the following search. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ren et al. World Journal of Surgical Oncology 2014, 12:55 Page 2 of 8
http://www.wjso.com/content/12/1/55algorithm: (cyclin D1 or CCND1) and (bladder cancer or
bladder tumor or bladder neoplasm or urothelial cancer
or urinary tract cancer) and prognos*. We evaluated po-
tentially relevant publications by examining their titles
and abstracts and all the studies matching the eligible
criteria were retrieved. We also checked the references
from retrieved articles and reviews to identify any add-
itional relevant studies. This study was planned, con-
ducted, and reported in adherence to the standards of
quality for reporting meta-analyses [8].
Inclusion criteria
Studies included in this meta-analysis had to meet all
the following criteria: i) to evaluate the correlation be-
tween cyclin D1 expression and prognosis of bladder
cancer patients; ii) to assess cyclin D1 expression in the
primary tumor tissues using immunohistochemistry
(IHC); and iii) to provide sufficient information allowing
for estimation of hazard ratios (HRs) and their 95% con-
fidence intervals (CIs). If multiple publications from the
same study population were available, the most recent
and detailed study was eligible for inclusion in the meta-
analysis.
Data extraction
Information was carefully extracted independently by
two authors according to the inclusion criteria noted
above. For each study, the following characteristics were
collected: the first author’s name, year of publication, the
country in which the study was carried out, sample size,
age of patients, follow-up years, disease stage, cut-off
value, increased cyclin D1 expression, and survival data.
Quality assessment
The quality of each study was assessed by the same two
investigators using the Newcastle-Ottawa Quality As-
sessment Scale for cohort studies with our reasonable
modifications (see “Newcastle-Ottawa quality assessment
scale” section). This scale is an eight-item instrument
that allows for assessment of patient population and se-
lection, study comparability, follow-up, and outcome of
interest. Interpretation of the scale is performed by
awarding points, or ‘stars’, for high-quality elements.
Stars are then added up and used to compare study
quality in a quantitative manner. The scores range from
0 to 9. We assigned scores of <7 and ≥7 for low and high
quality of studies, respectively.
Newcastle-Ottawa quality assessment scale
Selection
(1) Representativeness of the exposed cohort
(a) Truly representative of the average bladder
cancer (BCa) patients in the community*(b) Somewhat representative of the average BCa 2
patients in the community*
(c) Selected group of users (e.g., nurses, volunteers)
(d) No description of the derivation of the cohort
(2) Selection of the non-exposed cohort
(a) Drawn from the same community as the
exposed cohort*
(b) Drawn from a different source
(c) No description of the derivation of the non-
exposed cohort
(3) Ascertainment of exposure (Proof of BCa and
Cyclin-D1 measurement)




(4) Demonstration that outcome of interest was not




(1) Comparability of cohorts on the basis of the design
or analysis
(a) Study controls for smoking*
(b) Study controls for any additional factor (Age,
gender, grade, etc.)*Outcome
(1) Assessment of outcome




(2) Was follow-up long enough for outcomes to occur?
(Death or recurrence or progression)
(a) Yes (3 years)*
(b) No
(3) Adequacy of follow-up of cohorts
(a) Complete follow-up – all subjects accounted for*
(b) Subjects lost to follow-up unlikely to introduce
bias – small number lost – (25%) follow-up, or
description provided of those lost*
(c) Follow-up rate (≤75%) and no description of
those lost
(d) No statement
A study can be awarded a maximum of one star (*) for
each numbered item within the Selection and Outcome
categories. A maximum of two stars can be given for
Comparability. Underlined and quoted phrases are pro-
vided in the scale to allow for adjustment to particular
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the question relevant to this study.
Statistical methods
HRs and their 95% CIs were used to combine the data.
When these statistical variables were described in text or
tables, we obtained them directly from each trial publi-
cation. When not given explicitly in an article, they were
calculated from available numerical data in the articles
using methods reported by Parmar et al. [9]. In this
meta-analysis, DerSimonian-Laird random effect analysis
[10] was used, as a result of a priori assumptions about
the likelihood for heterogeneity. By convention, an ob-
served HR >1 implies worse survival for the group with
positive/increased cyclin D1 expression. The impact of
positive/increased cyclin D1 expression on survival was
considered to be statistically significant if the 95% CI did
not overlap with 1.
Homogeneity of ORs across studies was tested by a χ2-
based Q statistic and the I2 score. Heterogeneity was con-
sidered significant if the P value is <0.10. The value of I2 is
used to assess the degree of heterogeneity (I2 < 25% no het-
erogeneity; I2 = 25–50% moderate heterogeneity; I2 > 50%
large or extreme heterogeneity).
Evaluation of publication bias
Publication bias was assessed using Begg’s test (rank correl-
ation method) [11] and Egger’s test (linear regression
method) [12]. P <0.05 was considered to be representativeFigure 1 Process of study selection.of a significant statistical publication bias. All of the statis-
tical analyses were performed with STATA 11.0 (StataCorp,
College Station, TX, USA), using two-sided P values.
Results
Study selection and characteristics
A total of 85 articles were identified from a search of the
above databases using the search strategy as described
above (Figure 1). After exclusion of the trials that were
out of the scope of our systematic review, 17 studies
assessing prognostic value for survival of cyclin D1 sta-
tus in patients with bladder cancer were considered eli-
gible for inclusion in the evaluation. Upon further
review, 2 were excluded since it was not possible to
allow for the calculation of HR estimate because of in-
sufficient reported data, 1 was excluded because it had
overlapped data with other studies, and 1 was identified
through checking reference lists of retrieved studies.
After selection, a total of 15 publications [13-27] were fi-
nally enrolled for analysis of the prognostic value of cyc-
lin D1 expression in bladder cancer (Figure 1).
The clinical features of these 15 included studies (16
cohorts) eligible for the meta-analysis are summarized in
Table 1; 2 studies evaluated patients from Japan, 2 from
Korea, 2 from Italy, 2 from Spain, 1 from Finland, 1
from the UK, 1 from Switzerland, 1 from the USA, 1
from Greece, 1 from Sweden, and 1 from four countries
(Denmark, Sweden, Spain, and Taiwan). The 15 studies
comprised 2,591 patients, with sample sizes ranging
Table 1 Main characteristics of all studies included in the meta-analysis
Study Year Country Mean/median
age




Quality score Survival analysis Hazard ratios
Shin et al. [13] 1997 Korea 62 75 35 All 5 50.7 5 OS Estimated
Liukkonen et al. [14] 2000 Finland 65.8 187 58.8 Superficial 10 63.6 7 PFS Estimated
Takagi et al. [15] 2000 Japan 69.3 102 41 All NR 77 7 OS Estimated
Tut et al. [16] 2001 UK 68 150 33 All 8 83 5 OS Estimated
Sgambato et al. [17] 2002 Italy 68 96 50 Superficial 25 52.1 7 OS, RFS, DFS Estimated
Lopez-Beltran et al. [18] 2004 Spain 61 159 74.8 Superficial 15 33.3 7 OS, DFS Estimated
Mhawech et al. [19] 2004 Switzerland 70.3 101 19 Superficial 10 53.5 6 PFS Reported in text
Galmozzi et al. [20] 2006 Italy NR 82 21 Muscle-invasive 10 64.6 6 OS Reported in text
Yurakh et al. [21] 2006 Spain NR 84 36.4 All 10 NR 7 OS, PFS Reported in text
Shariat et al. [22] 2007 USA 63.2 74 42.3 Superficial 30 68.9 7 OS, RFS, PFS Estimated
Lee et al. [23] 2010 Korea 67 103 31.5 All 10 29 6 OS Reported in text
Levidou et al. [24] 2010 Greece 69 157 44.95 Muscle-invasive 40 NR 5 OS Reported in text
Behnsawy et al. [25] 2011 Japan NR 161 47 Superficial 20 24.8 7 RFS Reported in text
Olsson et al. [26] 2012 Sweden 73 201 60 Superficial 10 71 7 RFS, PFS Reported in text
Fristrup et al. A [27] 2013 Denmark 68 283 103 Superficial 20 NR 7 PFS Reported in text
Fristrup et al. B [27] 2013 Sweden, Spain, and Taiwan 71 576 80 Superficial 20 NR 7 PFS Reported in text
NR, not reported; OS, overall survival; RFS, recurrence-free survival; PFS, Progression-free survival; DFS, Disease-free survival; “Fristrup et al. A” here means the data in this row from Fristrup et al. [27] training cohort,
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enrolled less than 100 patients and 3 studies included
more than 200 patients. The follow-up period was at
least 19 months, while 11 cohorts were followed-up for
more than 3 years. HRs were recorded for each study
using available data or the methods described above.
Overall survival (OS) was reported in 10 studies,
progression-free survival (PFS) was reported in 7 studies,
recurrence-free survival (RFS) was reported in 4 studies,
and disease-free survival (DFS) was reported in 2 studies.
The points of study quality assessed by Newcastle-
Ottawa quality assessment scale ranged from 5 to 7
(with a mean of 6.4).
Cyclin D1 expression and OS in bladder cancer
Ten studies reported data on cyclin D1 expression and
OS in bladder cancer. Combined data from all the 10
studies showed that increased cyclin D1 levels were not
correlated with OS with a pooled HR estimate of 0.93
(95% CI: 0.83–1.04) (Figure 2). There was a significant
degree of heterogeneity (I2 = 60.8%, P = 0.006). Subgroup
analysis indicated that elevated cyclin D1 levels were sig-
nificantly associated with OS in muscle-invasive bladder
patients (HR: 0.95, 95% CI: 0.91–0.99), without signifi-
cant heterogeneity in the data (I2 = 0.0%, P = 0.456)
(Table 2).
Cyclin D1 expression and PFS in bladder cancer
Seven studies reported data on cyclin D1 expression and
PFS in bladder cancer. Combined data from all the 7 stud-
ies showed that increased cyclin D1 levels were significantly
correlated with PFS with a pooled HR estimate of 0.54Figure 2 Hazard ratios (HRs) and 95% confidence intervals (CIs) in stu
overall survival (OS).(95% CI: 0.32–0.92) (Figure 3). There was a significant de-
gree of heterogeneity (I2 = 93.8%, P <0.001).
Cyclin D1 expression and RFS in bladder cancer
Four studies reported data on cyclin D1 expression and
RFS in bladder cancer. Combined data from all the 4 stud-
ies showed that increased cyclin D1 levels were not corre-
lated with RFS with a pooled HR estimate of 0.94 (95% CI:
0.74–1.19). There was a significant degree of heterogeneity
(I2 = 71.2%, P = 0.015).
Cyclin D1 expression and DFS in bladder cancer
Two studies reported data on cyclin D1 expression and
DFS in bladder cancer. Combined data from these 2 studies
showed that increased cyclin D1 levels were not correlated
with DFS with a pooled HR estimate of 1.28 (95% CI: 0.22–
7.59). There was a significant degree of heterogeneity
(I2 = 92.0%, P <0.001).
Publication bias
A Begg’s funnel plot was presented for the visual assess-
ment of overt publication bias for the included cohorts in
cyclin D1 expression. The funnel plot shapes showed no
obvious evidence of asymmetry for OS and PFS. An Egger’s
test was then adopted for the formal evaluation (statistical
significance was set at P <0.05). The P value indicated that
there was no significant publication bias in OS (P = 0.607)
and PFS (P = 0.093) among these included studies.
Discussion
This meta-analysis aimed to examine the association be-
tween increased cyclin D1 expression and the prognosisdies assessing the relationship between cyclin D1 expression and
Table 2 Subgroup results of OS and heterogeneity test
Heterogeneity test
Variables Study number HR (95% CI) Q P I2 (%)
Total OS 10 0.93 (0.83–1.04) 22.95 0.006 60.8
Region
Asian 3 1.26 (0.44–3.62) 9.21 0.010 78.3
Caucasian 7 0.93 (0.86–1.02) 13.01 0.043 53.9
Sample size
>100 5 0.90 (0.55–1.47) 15.35 0.004 73.9
<100 5 0.86 (0.58–1.26) 7.44 0.114 46.2
Follow-up time (month)
>40 5 0.78 (0.50–1.21) 9.38 0.052 57.4
<40 5 0.98 (0.62–1.55) 13.33 0.010 70.0
Stage
Superficial 3 0.79 (0.32–1.96) 5.81 0.055 65.6
Muscle-invasive 2 0.95 (0.91–0.99) 0.56 0.456 0.0
All 5 0.92 (0.54–1.55) 16.17 0.003 75.3
Cut-off
>10% 4 0.87 (0.55–1.39) 6.07 0.108 50.5
≤10% 5 0.98 (0.62–1.55) 13.33 0.010 70.0
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outcomes of 2,591 bladder cancer patients from 15 indi-
vidual studies, indicating that altered cyclin D1 expres-
sion was not correlated with OS, RFS, and DFS of
bladder cancer patients, but was with PFS (HR: 0.54,
95% CI: 0.32–0.92). Subgroup analysis revealed that in-
creased cyclin D1 expression was also significantly asso-
ciated with good OS in muscle-invasive bladder cancer
patients (HR: 0.95, 95% CI: 0.91–0.99).Figure 3 Hazard ratios (HRs) and 95% confidence intervals (CIs) in stu
progression-free survival (PFS).Cyclin D1 has been extensively investigated in cancer
development and is seen as an important regulator of
the G1- to S-phase transition in the cell cycle [28]. In
addition, it also has been shown that cyclin D1 mediates
DNA repair [29]. Furthermore, cyclin D1 may be an im-
portant prognostic indicator for human cancer. Xu et al.
found that cyclin D1 overexpression impacts the prog-
nosis of ER-positive breast cancer patients, but not pa-
tients with unselected primary breast cancer or patientsdies assessing the relationship between cyclin D1 expression and
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http://www.wjso.com/content/12/1/55treated with neoadjuvant chemotherapy [30]. Zhao et al.
reported that cyclin D1 expression level detected by IHC
is associated with worst clinicopathological features and
prognosis for esophageal squamous cell carcinoma [31].
Rainsbury’s study indicated that nuclear cyclin D1 may
be a prognostic biomarker of survival in oropharyngeal
squamous cell carcinoma [32]. However, in the field of
bladder cancer, the search for a prognostic value of cyc-
lin D1 expression has produced different results. Thus, a
meta-analysis is essential to achieve a clearer picture of
the prognostic value of cyclin D1. To our knowledge, to
date, no meta-analysis regarding this relationship has
been published.
In recent years, molecular biomarkers have been exam-
ined for prognostic assessment despite results remaining in-
consistent and controversial. There are no molecular
markers that are routinely used in bladder cancer. In the
present meta-analysis, our results suggest that overexpres-
sion of cyclin D1 is a prognostic factor for good PFS in
bladder cancer patients. The clinical implication of this
finding is to help us to identify the subjects at high risk of
progression after surgery. Patients with lower expression of
cyclin D1 may be treated more carefully and followed
closely.
Our study had some important strengths. Previous stud-
ies have been reported inconsistent and conflicting results
about the association between cyclin D1 overexpression
and the prognosis of bladder cancer. As individual studies
may have insufficient statistical power, our study of 15 stud-
ies involving a large number of cases and participants has
enhanced statistical power to derive a more precise and re-
liable estimation of the relationship between them. None-
theless, several limitations of this meta-analysis should be
discussed.
First, although publication bias was not present for OS
and PFS, some inevitable publication bias may exist, be-
cause only studies published in English and Chinese
were included in our meta-analysis. Second, the number
of selected studies was still relatively small, and the sig-
nificant between-study heterogeneity was detected in
most comparisons, which may distort the meta-analysis.
Third, since some HRs were not directly reported in the
studies, we had to calculate them from the data provided
in the papers or extrapolate them from the survival
curves. The estimated HR might be less reliable than the
data obtained directly from published statistics.
Conclusions
In summary, despite the limitations, results of our meta-
analysis suggest that increased cyclin D1 expression is sig-
nificantly associated with good PFS in bladder cancer.
Whether it could be used as a predicative factor for clinical
assessment requires large-scale population studies among
different ethnicities and regions.Abbreviations
CI: Confidence interval; DFS: Disease-free survival; HRs: Hazard ratios;
IHC: Immunohistochemistry; OR: Odds ratio; OS: Overall survival;
PFS: Progression-free survival; RFS: Recurrence-free survival.
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